TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10417583

Group type: EXPERIMENTAL
Intervention: 2% kojic acid in a gel containing 10% glycolic acid and 2% hydroquinone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gel without kojic acid (control)
Number of subjects: 40
Study: 7570132

Group type: EXPERIMENTAL
Intervention: 1 mg morphine sulphate in 20 ml saline (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.25% bupivacaine (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 mg morphine sulphate in 20 ml of 0.25% bupivacaine (Group C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intra-articular injection (Group D)
Number of subjects: 40
Study: 2187555

Group type: EXPERIMENTAL
Intervention: Greasy tulle dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tincture of benzoin dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paraffin tulle dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soframycin addition to greasy tulle
Number of subjects: 0
Study: 7400107

Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (20 mg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard methylphenidate (10 mg twice daily)
Number of subjects: 30
Study: 29691998

Group type: EXPERIMENTAL
Intervention: TEAR treatment arms
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: RACAT treatment arms
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: TEAR treatment response
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: RACAT treatment response
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Overall AEs
Number of subjects: 755
Study: 28177481

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Medical treatment for chronic pain
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Prescribed drugs for pain relief
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Illicit drugs for pain relief
Number of subjects: 1287
Study: 26112662

Group type: EXPERIMENTAL
Intervention: Attachment-focused parent group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Home visiting
Number of subjects: 62
Study: 22718298

Group type: EXPERIMENTAL
Intervention: Rubber transcystic biliary drainage (TBD)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard silicone T-tube (TT)
Number of subjects: 248
Study: 20923790

Group type: EXPERIMENTAL
Intervention: Oral sildenafil
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate (MgSO₄)
Number of subjects: 65
Study: 19568178

Group type: EXPERIMENTAL
Intervention: 100 mg LDECA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg LDECA plus 30 mg lansoprazole
Number of subjects: 24
Study: 17301218

Group type: EXPERIMENTAL
Intervention: Env(+) infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Env(-) infants
Number of subjects: 0
Study: 15488799

Group type: EXPERIMENTAL
Intervention: Lidocaine tape
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 10
Study: 11238494

Group type: EXPERIMENTAL
Intervention: L-T(4) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 20
Study: 9894371

Group type: EXPERIMENTAL
Intervention: Loading dose (LD) budesonide (400 micrograms twice daily for 6 weeks, then 400 micrograms nocte for 12 weeks)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Static dose (SD) budesonide (400 micrograms nocte for 18 weeks)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Loading dose (LD) budesonide (400 micrograms twice daily for 6 weeks)
Number of subjects: 682
Study: 8115156

Group type: EXPERIMENTAL
Intervention: ProCell (DexSol with hEGF 10 ng/ml and insulin 10 micrograms/ml)
Number of subjects: 105

Group type: COMPARATOR
Intervention: DexSol (control group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ProCell (DexSol with hEGF and insulin)
Number of subjects: 105
Study: 2192194

Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 17
Study: 656353

Group type: EXPERIMENTAL
Intervention: Pilocarpine phenylephrine provocative test
Number of subjects: 68

Group type: COMPARATOR
Intervention: Dummy provocative test
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Peripheral iridectomy followed by reprovocation
Number of subjects: 68
Study: 30971516

Group type: EXPERIMENTAL
Intervention: Radiomics predictive model
Number of subjects: 160
Study: 28655801

Group type: EXPERIMENTAL
Intervention: BetterBirth Program (coaching-based implementation of the WHO Safe Childbirth Checklist)
Number of subjects: 0
Study: 25867399

Group type: EXPERIMENTAL
Intervention: Thoracic duct ligation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no thoracic duct ligation)
Number of subjects: 74
Study: 23602310

Group type: EXPERIMENTAL
Intervention: Computerized brain exercise program (Brain Fitness, Dakim Inc.) used 5 days a week for 20-25 minutes each day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All participants playing at least 40 sessions over 6 months
Number of subjects: 69
Study: 21900193

Group type: EXPERIMENTAL
Intervention: Weekly bortezomib induction followed by bortezomib-based maintenance
Number of subjects: 232
Study: 18769382

Group type: EXPERIMENTAL
Intervention: Enhanced kangaroo mother care (KMC) with rocking, singing, and sucking
Number of subjects: 90

Group type: COMPARATOR
Intervention: Simple kangaroo mother care (KMC) without additional stimulation
Number of subjects: 90
Study: 17299078

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 9
Study: 15341437

Group type: EXPERIMENTAL
Intervention: Steroid therapy (specific type and dosage not detailed)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 21
Study: 11686214

Group type: EXPERIMENTAL
Intervention: Rome II criteria
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Manning criteria
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Rome I criteria
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Drossman criteria
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Talley criteria
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Kay & Jorgensen criteria
Number of subjects: 2000
Study: 9692272

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/24 h for the first 6 months)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Naltrexone (control group)
Number of subjects: 112
Study: 7870278

Group type: EXPERIMENTAL
Intervention: CD4+CD45RA+ (T) lymphocytes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CD19+CD5+ (B) lymphocytes
Number of subjects: 9
Study: 2653554

Group type: EXPERIMENTAL
Intervention: Terodiline at 25 mg/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 31012599

Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation (NSI) daily for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no NSI)
Number of subjects: 20
Study: 30860117

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline as placebo (Group C)
Number of subjects: 19
Study: 29188890

Group type: EXPERIMENTAL
Intervention: Iberian cured-ham (ICH) enriched ad libitum diet
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (ad libitum diet without ICH)
Number of subjects: 102
Study: 24519403

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23549225

Group type: EXPERIMENTAL
Intervention: Duloxetine (30-90 mg for 12 weeks)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Routine ischemic stroke therapy (Control)
Number of subjects: 95
Study: 21720661

Group type: EXPERIMENTAL
Intervention: Dapsone gel 5% + tazarotene cream 0.1%
Number of subjects: 171

Group type: COMPARATOR
Intervention: Tazarotene cream 0.1%
Number of subjects: 171
Study: 19696119

Group type: EXPERIMENTAL
Intervention: Stretch intervention (experimental leg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-stretch intervention (control leg)
Number of subjects: 30
Study: 16488295

Group type: EXPERIMENTAL
Intervention: Low-dose UVA1 (20 J/cm2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Medium-dose UVA1 (50 J/cm2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Narrowband UVB
Number of subjects: 64
Study: 15605686

Group type: EXPERIMENTAL
Intervention: Diclofenac applied at a therapeutic dose of 60 mg/100 cm2 3 times daily for 4 days with occlusion for 4 hours.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diclofenac applied at a single dose of 300 mg/100 cm2 without occlusion.
Number of subjects: 6
Study: 11089744

Group type: COMPARATOR
Intervention: PEEP of 0 (ZEEP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PEEP of 5 cm H2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PEEP of 10 cm H2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PEEP of 15 cm H2O
Number of subjects: 10
Study: 9093253

Group type: EXPERIMENTAL
Intervention: Tryptophan-free mixture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nutritionally balanced mixture
Number of subjects: 15
Study: 8462386

Group type: EXPERIMENTAL
Intervention: Captopril (initial dose: 12.5 mg daily, increased according to tolerance)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untreated (Control Group B)
Number of subjects: 26
Study: 2939220

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg twice daily for 15 days, then 40 mg twice daily for 75 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol (80 mg twice daily for 90 days)
Number of subjects: 30
Study: 29648488

Group type: EXPERIMENTAL
Intervention: 3-week conductive education (CE) course(s) followed by conventional practice
Number of subjects: 21

Group type: COMPARATOR
Intervention: 4-month waiting list including conventional practice followed by CE courses
Number of subjects: 21
Study: 29756876

Group type: EXPERIMENTAL
Intervention: Machine learning combined with random structure searching (RSS) algorithms for constructing interatomic potential for boron.
Number of subjects: 0
Study: 27458223

Group type: EXPERIMENTAL
Intervention: Delamanid coadministered with tenofovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delamanid coadministered with efavirenz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delamanid coadministered with Kaletra (lopinavir/ritonavir)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delamanid coadministered with ethambutol plus Rifater (rifampin, pyrazinamide, isoniazid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delamanid
Number of subjects: 0
Study: 25275368

Group type: EXPERIMENTAL
Intervention: General anesthesia (propofol or sevoflurane)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Hypercapnia (increased end-tidal pressure by 4 and 8 mmHg during anesthesia)
Number of subjects: 224
Study: 22695168

Group type: EXPERIMENTAL
Intervention: 12 mm heel lifts (12HL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 18 mm heel lifts (18HL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No heel lifts (NHL)
Number of subjects: 10
Study: 20014137

Group type: EXPERIMENTAL
Intervention: VUS-CEUS
Number of subjects: 50

Group type: COMPARATOR
Intervention: CT
Number of subjects: 50
Study: 18272893

Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 610

Group type: COMPARATOR
Intervention: Intubation
Number of subjects: 610
Study: 15963379

Group type: EXPERIMENTAL
Intervention: Immediate reproduction trial with capital letters or abstract shapes; patients performed as proficiently as healthy subjects.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed reproduction trial with capital letters; patients failed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed reproduction trial with random shapes; patients did not fail.
Number of subjects: 0
Study: 15198156

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (75 mg bupivacaine heavy + 50 microg fentanyl)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (15 mg bupivacaine heavy + 50 microg fentanyl)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Saddle blockade (10 mg bupivacaine heavy + 50 microg fentanyl)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study: 10578977

Group type: EXPERIMENTAL
Intervention: CytoView prototype PT system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional glass slide PT format
Number of subjects: 0
Study: 8566268

Group type: EXPERIMENTAL
Intervention: Purified FSH and flare‐up GnRH‐a (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Purified FSH and long GnRH‐a (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: hMG and long GnRH‐a (Group D)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Purified FSH only (Group A)
Number of subjects: 40
Study: 1763794

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 104
Study: 6347154

Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no adjuvant immunotherapy)
Number of subjects: 52
Study: 30952568

Group type: EXPERIMENTAL
Intervention: Personalised psychosocial intervention (comprising a flexible toolkit of psychological-change methods, including contingency management to reinforce abstinence, recovery activities, and clinic attendance)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Personalised psychosocial intervention
Number of subjects: 273
Study: 30116859

Group type: EXPERIMENTAL
Intervention: Ketamine treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26909799

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/d
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 24399647

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (0.5‐0.8 milliequivalents per liter)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 22646475

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) prophylaxis during pregnancy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preference-elicitation using a visual analog scale (feeling thermometer)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Probability trade-off exercise
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Personalized decision analysis
Number of subjects: 100
Study: 19607731

Group type: EXPERIMENTAL
Intervention: MSP3 malaria vaccine (15 microg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MSP3 malaria vaccine (30 microg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control vaccine (Engerix B)
Number of subjects: 45
Study: 17688074

Group type: EXPERIMENTAL
Intervention: Alprostadil (MUSE) 250, 500, or 1000 microg, applied three times
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Alprostadil (MUSE)
Number of subjects: 314
Study: 15333080

Group type: EXPERIMENTAL
Intervention: Intracardiac repair
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 14
Study: 11588417

Group type: EXPERIMENTAL
Intervention: Chen Medium
Number of subjects: 32

Group type: COMPARATOR
Intervention: Optisol-GS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both media
Number of subjects: 32
Study: 9825420

Group type: EXPERIMENTAL
Intervention: Training workshop for community pharmacy personnel
Number of subjects: 492

Group type: COMPARATOR
Intervention: Intervention customers
Number of subjects: 492
Study: 7852065

Group type: EXPERIMENTAL
Intervention: Intravenous morphine sulfate (morphine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous morphine and subfascial angiocatheter lidocaine hydrochloride (lidocaine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous morphine and subfascial angiocatheter normal saline solution
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Subfascial angiocatheter lidocaine
Number of subjects: 80
Study: 2685362

Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories (50 mg every 8 hours)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories
Number of subjects: 41
Study: 31189334

Group type: EXPERIMENTAL
Intervention: Arm A (hard palate closure at 12 months)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Arm B (hard palate closure at 36 months)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Reference data from peers without cleft palate (CP)
Number of subjects: 143
Study: 28877711

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles 10 μg, 50 μg, or 100 μg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles 100 μg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 26
Study: 25440688

Group type: EXPERIMENTAL
Intervention: EUS‐FNA using 19GN
Number of subjects: 100
Study: 23645695

Group type: EXPERIMENTAL
Intervention: L-arginine (100 mg/kg tid)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21164372

Group type: EXPERIMENTAL
Intervention: ICGA (intraoperative near-infrared indocyanine green angiography)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Microvascular Doppler ultrasound
Number of subjects: 104

Group type: COMPARATOR
Intervention: Neuroendoscopy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combination of DSA and ICGA
Number of subjects: 104
Study: 18347491

Group type: EXPERIMENTAL
Intervention: Antibiotics (cephalexin)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 146
Study: 17227516

Group type: EXPERIMENTAL
Intervention: Unsated small-caliber endoscopy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 121
Study: 15530757

Group type: EXPERIMENTAL
Intervention: Action plan intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 88
Study: 11502832

Group type: EXPERIMENTAL
Intervention: High telomerase activity during the proliferative phase.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High telomerase activity at the onset of the luteal phase.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Decreased telomerase activity during the early luteal phase.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Telomerase activity disappeared by the midluteal phase.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moderate telomerase activity in the late luteal phase.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Inversely related serum progesterone levels to telomerase activity.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dynamic changes in endometrial telomerase activity during the menstrual cycle.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Relationship between sex steroid levels and telomerase regulation.
Number of subjects: 72
Study: 9423946

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 7516378

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) plus Tamoxifen (TAM)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: CPA plus Serenoa Repens
Number of subjects: 256
Study: 3544968

Group type: EXPERIMENTAL
Intervention: TECA 120 mg/day
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: TECA 60 mg/day
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 31994196

Group type: EXPERIMENTAL
Intervention: Phentolamine mesylate (1.7-mL OraVerse, 0.4-mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (1.7-mL sterile saline water)
Number of subjects: 66
Study: 29651711

Group type: EXPERIMENTAL
Intervention: Baclofen 45-60 mg/day for 3 months (n=37)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Treatment as usual (TAU, n=70)
Number of subjects: 107
Study: 28003052

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 25204553

Group type: EXPERIMENTAL
Intervention: pertuzumab-trastuzumab-docetaxel (PTD)
Number of subjects: 417

Group type: COMPARATOR
Intervention: trastuzumab-docetaxel (TD)
Number of subjects: 417
Study: 23609186

Group type: EXPERIMENTAL
Intervention: Brachytherapy (BCT) after EBRT-CT
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Radical hysterectomy (RH) after EBRT-CT
Number of subjects: 211
Study: 19902491

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents with IVUS guidance
Number of subjects: 210

Group type: COMPARATOR
Intervention: Drug-eluting stents without IVUS guidance
Number of subjects: 210
Study: 19055847

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 540

Group type: COMPARATOR
Intervention: No anticoagulation (Control)
Number of subjects: 540
Study: 17259789

Group type: EXPERIMENTAL
Intervention: T4-Ibsa oral solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Eutirox 100 tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: T3-Ibsa oral solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ti-tre tablets
Number of subjects: 24
Study: 12749488

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 833
Study: 10800972

Group type: EXPERIMENTAL
Intervention: Stage-based bedside counseling program supplemented with a videotape, self-help materials, and a follow-up telephone call
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1173
Study: 8630380

Group type: EXPERIMENTAL
Intervention: PIXY321, 375 microg/m2 twice a day subcutaneously
Number of subjects: 53

Group type: COMPARATOR
Intervention: GM-CSF, 250 microg/m2 daily subcutaneously
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: PIXY321
Number of subjects: 53

Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 53
Study: 1343144

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF or TMF chemotherapy
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with adrioblastin
Number of subjects: 569

Group type: COMPARATOR
Intervention: CMF and TMF chemotherapy
Number of subjects: 569